Related articles
Last Year’s DCT Is Today’s Clinical Trial
DCTs have transformed from a disruptive force challenging the norm to an integral concept, now widely embraced in the clinical trial landscape. Join us for this upcoming Clinical Leader Live session, where experts will explore the current landscape, highlighting the positive impact of DCTs and their transition from innovation to indispensable practice in the era of evidence generation and modern clinical trials.
Rapid evolution: How DCT’s DNA became standard in modern clinical trials
It’s impossible to deny how different clinical trials look almost four years after the pandemic revolutionized clinical research. Today, the digital and decentralized tools and technologies that enabled clinical trials to carry on through the COVID-19 pandemic are present (in some form) in nearly all clinical trials, a far cry from the dynamics of 2019.
The Digital Future is Now eBook
According to Grandview Research,the hybrid and decentralized clinicaltrial (DCT) market will be worth more than 12 billion dollars by 2030. Sparked by the COVID-19 pandemic of 2020, the rapid ascent of patient centered technology and the digital and decentralized trials they’ve spawned has forever changed the landscape of clinical conduct.